Billable / Specific Code
ICD-10-CM C50.011 is the diagnosis code for Malignant neoplasm of nipple and areola, right female breast. This code falls under the section "Malignant neoplasms of breast" within Chapter 2 — Neoplasms (C00-D49). It is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
Always refer to the official ICD-10-CM Tabular List for complete coding guidelines. Ensure documentation supports the specificity of the code selected. When in doubt, consult a certified medical coder or the latest CMS guidelines.
Understanding where C50.011 sits in the ICD-10-CM classification helps ensure proper coding:
Yes, C50.011 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
C50.011 is the ICD-10-CM diagnosis code for "Malignant neoplasm of nipple and areola, right female breast". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of C50.011 is C50.01 ("Malignant neoplasm of nipple and areola, female"). C50.011 provides a more specific classification within this category.
C50.011 is located in Section C50 — "Malignant neoplasms of breast" within Chapter 2 of the ICD-10-CM Tabular List.
Use C50.011 when the patients documented diagnosis matches "Malignant neoplasm of nipple and areola, right female breast" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Malignant neoplasm of nipple and areola, right female breast is C50.011.
Yes, C50.011 can be used as a primary diagnosis code since it is billable and specific.
C50.011 is in Chapter 2 of the ICD-10-CM Tabular List.
Yes, C50.011 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.